Insider Selling: Sionna Therapeutics (NASDAQ:SION) Director Sells 12,388 Shares of Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Bruce Booth sold 12,388 shares of the stock in a transaction that occurred on Tuesday, September 30th. The shares were sold at an average price of $30.06, for a total value of $372,383.28. Following the transaction, the director directly owned 794,110 shares of the company’s stock, valued at approximately $23,870,946.60. The trade was a 1.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Bruce Booth also recently made the following trade(s):

• On Wednesday, October 1st, Bruce Booth sold 200 shares of Sionna Therapeutics stock. The stock was sold at an average price of $29.95, for a total value of $5,990.00.
• On Monday, September 29th, Bruce Booth sold 66,105 shares of Sionna Therapeutics stock. The stock was sold at an average price of $30.09, for a total value of $1,989,099.45.

Sionna Therapeutics Trading Up 2.9%

NASDAQ SION opened at $29.30 on Friday. The stock has a 50 day moving average price of $22.85 and a 200-day moving average price of $17.19. Sionna Therapeutics, Inc. has a one year low of $7.26 and a one year high of $30.60.

Sionna Therapeutics (NASDAQ:SION) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.27.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Wall Street Zen upgraded Sionna Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 16th. Raymond James Financial assumed coverage on Sionna Therapeutics in a report on Tuesday, September 2nd. They issued a “strong-buy” rating and a $45.00 target price for the company. Royal Bank Of Canada assumed coverage on Sionna Therapeutics in a report on Wednesday, September 3rd. They set a “sector perform” rating and a $22.00 price target on the stock. Finally, Jones Trading assumed coverage on shares of Sionna Therapeutics in a research note on Monday, September 8th. They set a “buy” rating and a $46.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $38.00.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of SION. RA Capital Management L.P. purchased a new stake in shares of Sionna Therapeutics in the 1st quarter worth $109,258,000. TPG GP A LLC purchased a new position in shares of Sionna Therapeutics during the first quarter valued at $69,925,000. Atlas Venture Life Science Advisors LLC bought a new stake in shares of Sionna Therapeutics in the first quarter valued at about $38,639,000. Braidwell LP purchased a new stake in Sionna Therapeutics in the second quarter worth about $18,770,000. Finally, Jennison Associates LLC bought a new position in Sionna Therapeutics during the 1st quarter worth about $8,995,000.

About Sionna Therapeutics

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.